## ANALYTICAL METHOD PROCEDURES

TOTAL PAGES: 8

AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

## IMPURITIES DETERMINATION

General Index:

PRODUCT SPECIFICATIONS
IMPURITIES BY TLC
TLC SETUP
STANDARD PREPARATION
SAMPLE PREPARATION
PROCEDURE
CALCULATION
TYPICAL PLATES (SCHEMATIC)

Method is suitable for:

- ☑ In-process control
- Product Release
- ☑ Stability indicating analysis

ED. NO: NEW	Effective Date :	APPROVED:			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD
Abbreviated New Drug Application:		on: Sect:	16.24	Oral AZITHROMYC	IN SUSPENSION

## ANALYTICAL METHOD PROCEDURES

TOTAL PAGES: 8

#### AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

ASSAY SPE	CIFICATIONS		
PRODUCT:	AZITHROMYCIN SUSPENSION		
	200 mg/ 5mL		
Description Color Odor & Clarity	[White to light gray] uniform homogeneous <b>Suspension</b> with banana / vanilla flavor and odor		
Identification A:	The Chromatogram of the sample solution exhibits a peak with the same retention time as the standard solution		
Fill Volume [15.0 mL] (±5.0%) mL	Target 15.0		
Fill Volume [22.5 mL] (±5.0%) mL	Target 22.5		
pH (± 1.0 unit)	Target 10.0 Limit: 9.0 - 11.0		
Viscosity	Target 1200 Limit: 800 - 1800 cp		
Brookfield, Spindle #[ LV2] After [6]rpm			
Assay [for Stability]	Limit: 90.0 - 110.0% of labeled amount		
	[180.0] - [220.0] mg / [5] mL		
Impurity determination			
- Any Individual	NMT 0.5% of the labeled amount		
- IMP.1	NMT 0.8% of the labeled amount		
- IMP.2	NMT 0.5% of the labeled amount		
- Total:	NMT 2.0% of the labeled amount		
Container Closure system	50 mL HDPE Bottle with CRC HDPP Cap		
	Security Cap has twist off-tamper evident ring		
IMPURITIES KEY:-			
IMP1. N-Demethylazithromycin			
IMP2. Desosaminylazithromycin			

ED. N0: NEW	Effective Date :	<b>APPROVED:</b>			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD
Abbreviated New Drug Application:		on: Sect:	16.25	Oral AZITHROMYC	IN SUSPENSION

## ANALYTICAL METHOD PROCEDURES

TOTAL PAGES: 8

#### AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

A-124-02-0199
Silica gel 60 F254, 20x20cm plate with 250µ precoated layer
$100 \pm 3^{\circ}C / 10 min$
Dragendorff's reagent
Dragendorff's reagent
N/A
20µL
20µL
Chloroform : Methanol (1:1, v/v)
Apply $50\mu$ L of the Sample and Standard solutions as a 1.5cm long streak from the base line
2.5 cm from top of plate
Dark band in off-white background
Hexane : Ethyl acetate : Diethylamine (75 : 25 : 10 V/V) in a pre-saturated tank suitable for TLC chromatography for at least 1 hour with the vapors of the solvent system

#### SPECIAL NOTE AND CAUTION:

1. All solvents used must be of TLC grade.

2. All samples and standard solution must be protected from Light.

It is necessary to ensure that the chamber is kept covered throughout the spot resolution to prevent solvent loss.

ED. N0: NEW	Effective Date :	APPROVED:			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD

Abbreviated New Drug Application:

Oral AZITHROMYCIN SUSPENSION

## ANALYTICAL METHOD PROCEDURES

TOTAL PAGES: 8

#### AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

## STANDARD PREPARATION

The Analytical Standard refers to the following: Primary Reference Standard (A.S.);

#### STANDARD SOLUTIONS [A] / [B] / [C] / [D]

[A]. Accurately weigh 8.7mg of N-Demethylazithromycin A.S. into a 50mL volumetric flask. Dissolve in and make up to volume with Diluent (concentration equivalent to 0.7% of the concentration of Azithromycin in the Sample solution).

[B]. Accurately weigh 7.2mg of Desosaminylazithromycin A.S. into a 100mL volumetric flask. Dissolve in and make up to volume with Diluent (concentration equivalent to 0.3% of the concentration of Azithromycin in the Sample solution).

[C]. <u>Azithromycin Powder held at 5°C as a control</u>: Prepare the solution as directed in the sample preparation and use the clear supernatant as the control sample.

[D]. Accurately weigh about 10.5 mg Standard (AZITHROMYCIN AS) into a 200mL volumetric flask. Make up to volume with diluent and mix. Sonicate for 10 minutes to dissolve. (Concentration of solution equivalent to 0.2% of the concentration of Azithromycin in the Sample solution.)

#### **TEST SOLUTION**

Accurately weigh sufficient powder equivalent to 250mg of Azithromycin into a 10mL volumetric flask. Add about 5mL of Diluent and sonicate for 10 minutes. Make up to volume with Diluent and mix. Centrifuge this suspension for 10 minutes. Use the clarified extract for analysis.

**DILUENT** - Mixture of Chloroform : Methanol (1:1; V/V)

**Solvent System**: - Hexane : Ethyl acetate : Diethylamine (75 : 25 : 10 V/V) in a presaturated tank for at least 1 hour with the vapors of the solvent system.

This is the Mobile Phase for the TLC IMPURITY Test.

ED. N0: NEW	Effective Date :	APPROVED:			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD

## ANALYTICAL METHOD PROCEDURES

TOTAL PAGES: 8

#### AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

## PROCEDURE:

#### **CHROMATOGRAPHIC CONDITIONS**

■ Plate : Silica gel 60 F254 plate, Layer thickness = 0.25mm Pre-coated (E. Merck).

■ **Solvent system**: Hexane : Ethyl acetate : Diethylamine (75 : 25 : 10 V/V) in a suitable tank for TLC chromatography. Pre-saturate the tank with the solvent vapor system for not less than 30 minutes.

**Loading** : Separately apply equal volumes  $(20\mu L)$  of the Standard solutions A, B, C, D and the Sample solution as solutions as a 1.5cm long streak from the base line of the thin-layer plate.

■ Air-dry the plate for about 10 minutes before inserting into the tank.

■ **Development**: Note - All streaks on the plate must be completely dry before development.

Develop the plate in the tank up to 15cm (one pass).

**<u>Dragendorff's</u>** reagent Air-dry the plate for 5 minutes and then re-insert it into the developing chamber for a second pass. Remove the plate from the tank and allow to dry at room temperature.

#### **Detection** Reagents

#### **Dragendorff's Reagent:**

<u>Solution 1:</u> Weigh about 425mg of Bismuth subnitrate and dissolve in 25mL mixture of glacial acetic acid : water (20:80, V/V).

Solution 2: Weigh about 4g of Potassium iodide and dissolve in 10mL of water.

Solution 3: Weigh about 2.5g of Sodium nitrite and dissolve in 50mL of water.

Immediately prior to use, combine 5mL of Solution 1, 5mL of Solution 2 and 20mL of Glacial acetic acid. Dilute this solution to 100mL with water.

Spray the plate with the above mixture and air-dry the plate for 5-10 minutes. Finally spray the plate with Solution 3.

ED. N0: NEW	Effective Date :	APPROVED:			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD

Abbreviated New Drug Application:

**Oral AZITHROMYCIN SUSPENSION** 

Sect: 16.28

## ANALYTICAL METHOD PROCEDURES

TOTAL PAGES: 8

#### AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

## CALCULATION.

Measure the length of the Test and Reference Standard spots (impurities) from the base line and divide by the length of the solvent front. This is the Rf value. Calculate the Rf of the Sample [ $C_{38}H_{72}N_2 O_{12}$ ] Calculate the Rf of the Standard [ $C_{38}H_{72}N_2 O_{12}$ ]

### ACCEPTANCE CRITERIA

The relative mobility (Rf) of the main streak produced by the Sample solution (about 0.55) should correspond to that produced by the Standard solution C.

The streak at Rf of about 0.18 in the Sample solution exhibits an intensity not greater than the corresponding streak in the Standard solution A.

The streak at Rf of about 0.42 in the Sample solution exhibits an intensity not greater than the corresponding streak in the Standard solution B.

For evaluating other additional or existing streaks compare the chromatogram of the Sample solution with the chromatogram of the Standard solution D (5°C control powder for suspension).

The intensity of any additional streaks (not existing in Standard solution D) as well as any increase in intensity of existing bands, is less than that of the band, produced by the Standard Solution C.

ED. N0: NEW	Effective Date :	APPROVED:			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD
Abbreviated Nev	v Drug Applicatio	on: Sect:	16. <b>29</b>	Oral AZITHROMYC	IN SUSPENSION

## ANALYTICAL METHOD PROCEDURES

TOTAL PAGES: 8

AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

## CALCULATION.

Measure the length of the Test and Reference spots from the base line and divide by the length of the solvent front. These are the Rf values. Calculate the Rf of the Test  $[C_{38}H_{72}N_2 O_{12}]$ 

Calculate the Rf of the Standard  $[C_{38}H_{72}N_2 O_{12}]$ 

Spot length/Solvent front = Rf.  $T^1$  = Rf.  $S^1$ 

# $\frac{\text{Rf Test}}{\text{Rf Std}} = \text{Relative Rf Value} \approx 1.0$

## CONCLUSION.

Method **A-224-02-0199** is suitable stability indicating TLC analysis for the identification of the potential impurity profile of the active material in the dosage form.

ED. N0: NEW	Effective Date :	APPROVED:			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD
Abbreviated New	v Drug Applicatio	on: Sect:	16. <b>30</b>	Oral AZITHROMYC	IN SUSPENSION

ANDA Development

## ANALYTICAL METHOD PROCEDURES


TOTAL PAGES: 8

#### AZITHROMYCIN POWDER FOR ORAL SUSPENSION - 200mg Azithromycin Dihydrate per 5mL suspension after reconstitution as Anhydrous Azithromycin IMPURITIES BY TLC FOR STABILITY STUDIES

## TYPICAL CHROMATOGRAM

(Representative TLC Chromatogram)

IMP1. N-Demethylazithromycin A.S. IMP2.Desosaminylazithromycin A.S



NB: Chromatogram has been resolved horizontally for clarity

ED. N0: NEW	Effective Date :	APPROVED:			
Ed. Status :	DD / MM / 199Y	C. Latham	Edanna Holman	C Frost	Pat West
ORIGINAL		ANALYST	SUPERVISOR	QC	HEAD
<b>Abbreviated New</b>	v Drug Applicatio	on: Sect:	16.31	Oral AZITHROMYC	IN SUSPENSION

ANDA Development